Compare BAK & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAK | GPCR |
|---|---|---|
| Founded | 1972 | 2016 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2023 |
| Metric | BAK | GPCR |
|---|---|---|
| Price | $2.93 | $68.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $4.40 | ★ $97.90 |
| AVG Volume (30 Days) | 784.0K | ★ 2.4M |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,841,708,237.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.32 | $13.22 |
| 52 Week High | $5.10 | $94.90 |
| Indicator | BAK | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 68.61 |
| Support Level | $2.78 | $61.87 |
| Resistance Level | $3.13 | $72.00 |
| Average True Range (ATR) | 0.12 | 7.83 |
| MACD | -0.00 | 0.38 |
| Stochastic Oscillator | 51.09 | 48.10 |
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.